uPAR siRNA (h) from Santa Cruz Biotechnology, Inc. | Biocompare.com

Supplier Images

uPAR siRNA (h)

Be the first to write a review!

Citations:

Supplier Page from
Santa Cruz Biotechnology, Inc. for
uPAR siRNA (h)

Description

uPAR siRNA (h)

Product Specs
ItemuPAR siRNA (h)
CompanySanta Cruz Biotechnology, Inc.
Price $293.00Supplier Page View Company Product Page
Catalog Numbersc-36781
Gene Nameplasminogen activator, urokinase receptor
Quantity10 µM
Specieshuman
NCBI Full Gene Nameplasminogen activator, urokinase receptor
NCBI Gene AliasesCD87, U-PAR, UPAR, URKR
TypesiRNA/dsRNA

Add to Compare List

Santa Cruz Biotechnology, Inc.

Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

Company Profile

Website: http://www.scbt.com/

(1) Mesenchymal stem cells derived from human induced pluripotent stem cells improve the engraftment of myogenic cells by secreting urokinase-type plasminogen activator receptor (uPAR)Stem cell research & therapyOctober 9, 2021Elhussieny A, Nogami K, Sakai-Takemura F, Maruyama Y, Takemura N, Soliman WT, Takeda S, Miyagoe-Suzuki Y.

(2) TLR4 Response to LPS Is Reinforced by Urokinase ReceptorFrontiers in immunologyJanuary 1, 2020Kiyan Y, Tkachuk S, Rong S, Gorrasi A, Ragno P, Dumler I, Haller H, Shushakova N.

(3) Resveratrol Targets Urokinase-Type Plasminogen Activator Receptor Expression to Overcome Cetuximab-Resistance in Oral Squamous Cell CarcinomaScientific reportsAugust 21, 2019Uzawa K, Amelio AL, Kasamatsu A, Saito T, Kita A, Fukamachi M, Sawai Y, Toeda Y, Eizuka K, Hayashi F, et al.

(4) Transcriptomic pathway analysis of urokinase receptor silenced breast cancer cells: a microarray studyOncotargetNovember 24, 2017Narayanaswamy PB, Baral TK, Haller H, Dumler I, Acharya K, Kiyan Y.

(5) MicroRNA-335-5p Plays Dual Roles in Periapical Lesions by Complex Regulation PathwaysJ EndodAugust 1, 2017Yue J, Wang P, Hong Q, Liao Q, Yan L, Xu W, Chen X, Zheng Q, Zhang L, Huang D.

(6) Imaging active urokinase plasminogen activator in prostate cancerCancer researchApril 1, 2015LeBeau AM, Sevillano N, Markham K, Winter MB, Murphy ST, Hostetter DR, West J, Lowman H, Craik CS, VanBrocklin HF.

(7) Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistanceTheranosticsJanuary 1, 2014LeBeau AM, Sevillano N, King ML, Duriseti S, Murphy ST, Craik CS, Murphy LL, VanBrocklin HF.

(8) Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancerCancer researchApril 1, 2013LeBeau AM, Duriseti S, Murphy ST, Pepin F, Hann B, Gray JW, VanBrocklin HF, Craik CS.

(9) Suppression of FOXQ1 in benzyl isothiocyanate-mediated inhibition of epithelial-mesenchymal transition in human breast cancer cellsCarcinogenesisApril 1, 2013Sehrawat A, Kim SH, Vogt A, Singh SV.

(10) uPAR regulates pericellular proteolysis through a mechanism involving integrins and fMLF-receptorsThrombosis and haemostasisFebruary 1, 2013Montuori N, Cosimato V, Rinaldi L, Rea VE, Alfano D, Ragno P.

(11) Design, synthesis, biochemical studies, cellular characterization, and structure-based computational studies of small molecules targeting the urokinase receptorBioorganic & medicinal chemistryAugust 1, 2012Wang F, Eric Knabe W, Li L, Jo I, Mani T, Roehm H, Oh K, Li J, Khanna M, Meroueh SO.

(12) BioKnife, a uPA activity-dependent oncolytic Sendai virus, eliminates pleural spread of malignant mesothelioma via simultaneous stimulation of uPA expressionMolecular therapy : the journal of the American Society of Gene TherapyApril 1, 2012Morodomi Y, Yano T, Kinoh H, Harada Y, Saito S, Kyuragi R, Yoshida K, Onimaru M, Shoji F, Yoshida T, et al.

(13) Degradation of internalized αvβ5 integrin is controlled by uPAR bound uPA: effect on β1 integrin activity and α-SMA stress fiber assemblyPloS oneJanuary 1, 2012Wang L, Pedroja BS, Meyers EE, Garcia AL, Twining SS, Bernstein AM.

(14) Participation of the urokinase-type plasminogen activator receptor (uPAR) in neutrophil transendothelial migrationMolecular immunologyMay 1, 2011Pliyev BK, Antonova OA, Menshikov M.

(15) Factor XII: new life for an old proteinThrombosis and haemostasisNovember 1, 2010Schmaier AH, Larusch G.

(16) Downregulation of E-cadherin is an essential event in activating beta-catenin/Tcf-dependent transcription and expression of its target genes in Pdcd4 knockdown cellsOncogeneJanuary 7, 2010Wang Q, Sun ZX, Allgayer H, Yang HS.

(17) Urokinase-receptor-mediated phenotypic changes in vascular smooth muscle cells require the involvement of membrane raftsThe Biochemical journalOctober 12, 2009Kiyan J, Smith G, Haller H, Dumler I.

(18) Inactivation of uPA and its receptor uPAR by 3,3'-diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migrationJournal of cellular biochemistryJune 1, 2009Ahmad A, Kong D, Sarkar SH, Wang Z, Banerjee S, Sarkar FH.

(19) Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancerNeoplasia (New York, N.Y.)February 1, 2009Büchler P, Reber HA, Tomlinson JS, Hankinson O, Kallifatidis G, Friess H, Herr I, Hines OJ.

Be the First to Write a Review!